Strs Ohio Purchases New Shares in Agios Pharmaceuticals, Inc. $AGIO

Strs Ohio purchased a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 8,200 shares of the biopharmaceutical company’s stock, valued at approximately $240,000.

A number of other large investors also recently made changes to their positions in the company. Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals during the first quarter valued at about $133,000. SCS Capital Management LLC bought a new position in shares of Agios Pharmaceuticals during the first quarter valued at about $17,905,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Agios Pharmaceuticals by 19.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 147,276 shares of the biopharmaceutical company’s stock valued at $4,315,000 after purchasing an additional 24,441 shares in the last quarter. Woodline Partners LP bought a new position in shares of Agios Pharmaceuticals during the first quarter valued at about $597,000. Finally, Goldman Sachs Group Inc. lifted its position in shares of Agios Pharmaceuticals by 16.1% during the first quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock valued at $19,299,000 after purchasing an additional 91,482 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $56.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, September 4th. Bank of America decreased their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. Finally, Scotiabank decreased their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a report on Monday, July 28th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $56.00.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO opened at $37.32 on Thursday. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58. The company has a 50-day simple moving average of $37.53 and a 200 day simple moving average of $33.45. The company has a market capitalization of $2.17 billion, a PE ratio of 3.39 and a beta of 0.87.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The business had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. As a group, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CEO Brian Goff sold 11,085 shares of Agios Pharmaceuticals stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $36.67, for a total value of $406,486.95. Following the completion of the transaction, the chief executive officer owned 123,528 shares in the company, valued at $4,529,771.76. This trade represents a 8.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Scadden sold 1,400 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $40.00, for a total transaction of $56,000.00. Following the completion of the transaction, the director owned 17,603 shares of the company’s stock, valued at $704,120. The trade was a 7.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,036 shares of company stock worth $1,369,980 over the last three months. Company insiders own 4.30% of the company’s stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.